Axitinib as a third or further line of treatment in renal cancer: a single institution experience

Abstract

Background: Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeutic algorithm of RCC patients and the survival outcomes have changed dramatically. Methods: Herein we present a retrospective study of the patients treated in our Department with an antiangiogenic agent-Axitinib, a tyrosine kinase inhibitor-as a third or further line treatment. Statistical analysis was performed with SPSS, including the available clinicopathological data of the patients included. Results: Axitinib was found to be active in patients who received this treatment beyond second line. The toxicity profile of this regimen did not reveal any unknown adverse events. Conclusions: Our real world data reflect that axitinib is a safe and effective option, even beyond the second line.

Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective–prospective cohort multicentre study

“…The AXIS study compared axitinib and sorafenib and found that axitinib led to significantly higher PFS in secondline therapy (6.7 months vs. 4.7 months) (Rini et al 2011). Experience from a single institution in Greece indicated that axitinib is effective beyond second-line treatment (Tsironis et al 2020). A study in Italy showed a PFS of 7.14 months for axitinib after sunitinib (Facchini et al 2019).…”

Targeting receptor tyrosine kinase signaling: Avenues in the management of cutaneous squamous cell carcinoma

“… 78 , 79 Potent inhibitors of VEGFRs 1–3 such as axitinib and bevacizumab are being used in the treatment of renal cell carcinoma and epithelial ovarian, fallopian tube, or primary peritoneal cancer respectively. 80 , 81 As aberrant activation and regulation of these receptors have been extensively observed in development of cSCC. The major RTK inhibitors have been summarized in Table 1 and the use of these inhibitors might be an efficient strategy for the treatment of cSCC.…”

Combination of Interferons for Advanced Renal Cell Carcinoma

“…Regarding kinase inhibitors, axitinib has been used in numerous investigations for CRC, a retrospective study [40] where it was used as third or fourth line of treatment in patients with advanced kidney cancer, raised a mean PFS of 6.27 months and OS of 19.2 months. For metastatic patients treated with axitinib [41], 5.7 months of PFS were reported, with 15.4 OS.…”

“…Regarding kinase inhibitors, axitinib referred by other cite [40] caused grade 3 and higher toxicity in 31% of patients and the dose had to be reduced in 5 (22%) cases and the drug had to be suspended in 3 patients (13%). Other authors [41] reported grade 3 or 4 treatment-related AEs in 79% and 26% of patients.…”